UROLOGY waiting list data from England showed substantial reductions in long wait pathways. The findings come from a population-level analysis of referral to treatment pathways that examined the distribution of waiting times rather than headline list size alone.
The researchers analysed monthly incomplete pathway data from April 2024 to February 2026.
By February 2026, there were 385,949 incomplete urology pathways, representing a 7.8% reduction from 418,444 recorded in April 2024.
The proportion of pathways completed within 18 weeks increased from 57.3% to 63.9%, while the 92nd percentile waiting time fell from 45.6 weeks to 39.1 weeks.
Trend modelling showed a monthly reduction in total incomplete pathways of 0.38% and a monthly improvement in the proportion within 18 weeks of 0.31 percentage points.
The researchers noted that these associations with time could not be attributed to any single policy intervention.
The most marked improvement was observed among patients waiting the longest. Pathways exceeding 52 weeks decreased from 18,821 to 6,799, representing a 63.9% reduction.
There were also 448 pathways beyond 65 weeks and 91 beyond 78 weeks by February 2026.
Despite these gains, a large gap remained relative to the operational target that more than 92% of incomplete pathways should be within 18 weeks.
The analysis estimated an integer gap of 108,550 pathways in February 2026. In addition, urology services remained 4,343 within 18-week pathways short of the interim 65% benchmark.
Researchers highlighted that 139,425 pathways, or 36.1% of the total, remained beyond 18 weeks.
This equated to an estimated 1,866,427 pathway weeks beyond the 18-week threshold, demonstrating a considerable volume of accumulated waiting time.
Among 23 treatment functions assessed in February 2026, urology ranked seventh for both total incomplete pathways and pathways exceeding 52 weeks.
Performance within 18 weeks was 63.9%, slightly above the estimated national value of 62.6%, although both figures remained below the 65% interim benchmark.
The researchers emphasised that these metrics reflected operational burden rather than clinical outcomes.
The dataset did not provide information on indication, urgency, cancer status, symptoms, demographics, or patient harm. As a result, distributional measures may be used to complement patient level clinical prioritisation rather than replace it.
Drobot RB. Distributional burden of the English urology elective waiting list after the 2024 reporting reset. Sci Rep. 2026;DOI:10.1038/s41598-026-70336-5.
Featured image: DC Studio on Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
